490 related articles for article (PubMed ID: 23962714)
1. Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies.
Abbasalizadeh S; Baharvand H
Biotechnol Adv; 2013 Dec; 31(8):1600-23. PubMed ID: 23962714
[TBL] [Abstract][Full Text] [Related]
2. The safety of human pluripotent stem cells in clinical treatment.
Simonson OE; Domogatskaya A; Volchkov P; Rodin S
Ann Med; 2015; 47(5):370-80. PubMed ID: 26140342
[TBL] [Abstract][Full Text] [Related]
3. Regulatory considerations for the development of autologous induced pluripotent stem cell therapies.
Carpenter MK; Couture LA
Regen Med; 2010 Jul; 5(4):569-79. PubMed ID: 20632860
[TBL] [Abstract][Full Text] [Related]
4. Raising the standard: changes to the Australian Code of Good Manufacturing Practice (cGMP) for human blood and blood components, human tissues and human cellular therapy products.
Wright C; Velickovic Z; Brown R; Larsen S; Macpherson JL; Gibson J; Rasko JE
Pathology; 2014 Apr; 46(3):177-83. PubMed ID: 24614714
[TBL] [Abstract][Full Text] [Related]
5. Process engineering of human pluripotent stem cells for clinical application.
Serra M; Brito C; Correia C; Alves PM
Trends Biotechnol; 2012 Jun; 30(6):350-9. PubMed ID: 22541338
[TBL] [Abstract][Full Text] [Related]
6. GMP scale-up and banking of pluripotent stem cells for cellular therapy applications.
Ausubel LJ; Lopez PM; Couture LA
Methods Mol Biol; 2011; 767():147-59. PubMed ID: 21822873
[TBL] [Abstract][Full Text] [Related]
7. Autologous, allogeneic, induced pluripotent stem cell or a combination stem cell therapy? Where are we headed in cartilage repair and why: a concise review.
Vonk LA; de Windt TS; Slaper-Cortenbach IC; Saris DB
Stem Cell Res Ther; 2015 May; 6(1):94. PubMed ID: 25976213
[TBL] [Abstract][Full Text] [Related]
8. Bioreactor design for clinical-grade expansion of stem cells.
dos Santos FF; Andrade PZ; da Silva CL; Cabral JM
Biotechnol J; 2013 Jun; 8(6):644-54. PubMed ID: 23625834
[TBL] [Abstract][Full Text] [Related]
9. Manufacturing models permitting roll out/scale out of clinically led autologous cell therapies: regulatory and scientific challenges for comparability.
Hourd P; Ginty P; Chandra A; Williams DJ
Cytotherapy; 2014 Aug; 16(8):1033-47. PubMed ID: 24856894
[TBL] [Abstract][Full Text] [Related]
10. Clinical-scale purification of pluripotent stem cell derivatives for cell-based therapies.
Rodrigues GM; Rodrigues CA; Fernandes TG; Diogo MM; Cabral JM
Biotechnol J; 2015 Aug; 10(8):1103-14. PubMed ID: 25851544
[TBL] [Abstract][Full Text] [Related]
11. Human pluripotent stem cell-derived products: advances towards robust, scalable and cost-effective manufacturing strategies.
Jenkins MJ; Farid SS
Biotechnol J; 2015 Jan; 10(1):83-95. PubMed ID: 25524780
[TBL] [Abstract][Full Text] [Related]
12. Culturing human pluripotent stem cells for regenerative medicine.
Ozawa H; Matsumoto T; Nakagawa M
Expert Opin Biol Ther; 2023; 23(6):479-489. PubMed ID: 37345510
[TBL] [Abstract][Full Text] [Related]
13. cGMP-Manufactured Human Induced Pluripotent Stem Cells Are Available for Pre-clinical and Clinical Applications.
Baghbaderani BA; Tian X; Neo BH; Burkall A; Dimezzo T; Sierra G; Zeng X; Warren K; Kovarcik DP; Fellner T; Rao MS
Stem Cell Reports; 2015 Oct; 5(4):647-59. PubMed ID: 26411904
[TBL] [Abstract][Full Text] [Related]
14. Stable propagation of human embryonic and induced pluripotent stem cells on decellularized human substrates.
Abraham S; Sheridan SD; Miller B; Rao RR
Biotechnol Prog; 2010; 26(4):1126-34. PubMed ID: 20730767
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic cell therapy manufacturing: process development technologies and facility design options.
Abbasalizadeh S; Pakzad M; Cabral JMS; Baharvand H
Expert Opin Biol Ther; 2017 Oct; 17(10):1201-1219. PubMed ID: 28699788
[TBL] [Abstract][Full Text] [Related]
16. Current applications of human pluripotent stem cells: possibilities and challenges.
Ho PJ; Yen ML; Yet SF; Yen BL
Cell Transplant; 2012; 21(5):801-14. PubMed ID: 22449556
[TBL] [Abstract][Full Text] [Related]
17. Autologous Induced Pluripotent Stem Cell-Based Cell Therapies: Promise, Progress, and Challenges.
Madrid M; Sumen C; Aivio S; Saklayen N
Curr Protoc; 2021 Mar; 1(3):e88. PubMed ID: 33725407
[TBL] [Abstract][Full Text] [Related]
18. [Regulatory science research to facilitate the development of cell/tissue-processed products].
Sato Y; Tsutsumi H; Sawada R; Suzuki T; Yasuda S
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2013; (131):16-9. PubMed ID: 24340665
[TBL] [Abstract][Full Text] [Related]
19. Clinical-Grade Human Pluripotent Stem Cells for Cell Therapy: Characterization Strategy.
Rehakova D; Souralova T; Koutna I
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244538
[TBL] [Abstract][Full Text] [Related]
20. Concise review: making and using clinically compliant pluripotent stem cell lines.
Carpenter MK; Rao MS
Stem Cells Transl Med; 2015 Apr; 4(4):381-8. PubMed ID: 25722426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
